Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neoadjuvant hormonal therapy: the Canadian experience

F Labrie1, L Cusan, J L Gomez

  • 1Prostate Cancer Research Unit, Centre Hospitalier Universitaire de Québec (CHUQ), Laval University Medical Center, Canada.

Urology
|March 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reduced cerebrospinal fluid monoamines in Alexander's disease: a clue to a symptomatic therapy.

European journal of neurology·2018
Same author

New chemical and radiochemical routes to [<sup>18</sup>F]Rho6G-DEG-F, a delocalized lipophilic cation for myocardial perfusion imaging with PET.

MedChemComm·2017
Same author

Hereditary colorectal cancer registries in Canada: report from the Colorectal Cancer Association of Canada consensus meeting; Montreal, Quebec; October 28, 2011.

Current oncology (Toronto, Ont.)·2013
Same author

Histological study of stem-like cells in human colon adenocarcinoma at different stages of the disease.

Biotechnic & histochemistry : official publication of the Biological Stain Commission·2013
Same author

Structure, function and tissue-specific gene expression of 3β-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase enzymes in classical and peripheral intracrine steroidogenic tissues.

The Journal of steroid biochemistry and molecular biology·2012
Same author

Steroidogenesis in guinea pig adrenal cortex: effects of ACTH on steroid secretion and steroidogenic enzyme activities and expression.

The Journal of steroid biochemistry and molecular biology·2012

Neoadjuvant combination therapy using flutamide and an LHRH agonist significantly improved surgical outcomes for early-stage prostate cancer. This treatment reduced positive surgical margins and increased organ-confined disease rates, suggesting potential survival benefits.

Area of Science:

  • Uro-oncology
  • Medical oncology
  • Surgical oncology

Background:

  • Radical prostatectomy is a primary treatment for early-stage prostate cancer.
  • Neoadjuvant therapy aims to improve surgical outcomes and potentially reduce cancer recurrence.
  • Combination therapy with antiandrogens and LHRH agonists is explored for prostate cancer treatment.

Purpose of the Study:

  • To evaluate the impact of neoadjuvant flutamide and LHRH agonist therapy on histopathologic findings.
  • To assess changes in serum prostate-specific antigen (PSA) levels post-neoadjuvant therapy.
  • To compare outcomes of neoadjuvant therapy followed by surgery versus surgery alone.

Main Methods:

  • 161 patients with stage B or C prostate cancer were randomized.
  • Treatment arms included radical prostatectomy alone or 3 months of neoadjuvant flutamide and LHRH agonist therapy before surgery.

Related Experiment Videos

  • Histopathologic findings and serum PSA levels were analyzed.

    • Main Results:

    • Neoadjuvant therapy reduced positive surgical margins from 33.8% to 7.8%.
    • Organ-confined disease increased from 49.3% to 77.8% after neoadjuvant treatment.
    • A strong correlation was observed between PSA levels and disease stage at surgery.

    Conclusions:

    • Neoadjuvant combination therapy significantly improves histopathologic outcomes in early-stage prostate cancer.
    • The observed improvements suggest a potential reduction in prostate cancer morbidity and mortality.
    • Long-term survival data are needed to confirm the overall impact on patient outcomes.